GLP-1 Drugs Like Ozempic and Mounjaro May Help Save Limbs and Lives in Diabetes Patients With PAD

A new study adds to the growing list of reasons doctors like GLP-1 medications. This time, the focus isn’t weight loss or blood sugar. It’s peripheral artery disease, a condition doctors find hard to treat and one that can lead to amputations.

Researchers at Cleveland Clinic reviewed health records from more than 2,000 adults with both type 2 diabetes and PAD, a disease that narrows the arteries in the legs and restricts blood flow. They wanted to compare outcomes for patients taking GLP-1 receptor agonists against those taking metformin, still the standard first drug for type 2 diabetes.

The results appeared in the Journal of the American Heart Association, and they were striking. Patients taking GLP-1 RAs had a 26 percent lower risk of dying from any cause than those taking metformin. They also visited the hospital less often, with hospitalizations dropping 13 percent.

The numbers around limb loss stand out even more. GLP-1 users saw their risk of amputation fall by as much as 48 percent. They also needed fewer procedures to restore blood flow in their legs, with that number dropping by roughly 36 percent.

Interestingly, rates of heart attack, stroke, and serious kidney problems stayed similar between both groups. So this doesn’t look like broad cardiovascular protection. Instead, it points to something more specific happening in the legs and in overall survival.

For readers unfamiliar with this drug class, GLP-1 RAs include semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro. These drugs mimic a gut hormone that boosts insulin release, lowers glucagon, and slows digestion. Together, these effects lower blood sugar and often trigger significant weight loss.

Researchers suspect something else may be happening too. These medications appear to calm inflammation in blood vessels and improve how the inner lining of arteries functions. Since inflammation and poor endothelial health both drive PAD, this mechanism could explain the limb benefits.

All three drugs remain prescription-only, and the FDA regulates their approved uses. Those uses differ slightly depending on whether a patient needs diabetes management or weight loss treatment.

Not everyone in the study benefited equally, though. Patients with more severe PAD, including chronic limb-threatening ischemia, saw the biggest improvements. People with a BMI of 30 or higher, meeting the clinical threshold for obesity, also showed stronger results.

Study co-author Akiva Rosenzveig explained that obesity and advanced PAD often share the same root problems. Insulin resistance, oxidative stress, and arterial stiffening tend to occur together. Because GLP-1 RAs seem to address several of these issues at once, the sickest patients may benefit the most.

This study looked backward at existing medical records rather than following a controlled trial design. That distinction matters, since it means the findings show a strong association rather than direct proof of cause and effect. Researchers still need clinical trials to confirm the link.

The team strengthened their comparison. Patients in the metformin group needed at least five prescriptions filled, and none of them could have any history of GLP-1 use during the study period. This approach helped reduce the chance of mixing up patients between the two groups.

Even so, the study authors remain cautious about overstating their findings. They’re calling for prospective clinical trials before doctors treat this as a standard recommendation for PAD care.

Still, this research gives doctors something to think about. Type 2 diabetes and PAD often occur together, and treatment options for that combination remain limited. This evidence probably won’t replace existing care, but it may soon shape the conversation around it.

Cost remains a real barrier, though. GLP-1 medications carry a high price tag, and insurance coverage varies depending on the reason for the prescription. Medicare and Medicaid often base coverage decisions on specific diagnosis codes, which can limit access even when a drug might genuinely help a patient.

For now, this study adds solid evidence to a growing body of research. It suggests GLP-1 drugs do more than manage blood sugar and appetite. Whether these findings eventually reshape treatment guidelines will depend on the clinical trials that follow.